The awards include stock options for 18,000 shares and RSUs for 23,600 shares, granted outside the company’s 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics said its Compensation Committee granted inducement equity awards on July 10, 2026 to six new employees, covering a total of 41,600 shares of common stock. The grants consist of non-qualified stock options to purchase 18,000 shares and restricted stock units, or RSUs, covering 23,600 shares. The awards are subject to the terms of Travere’s 2018 Equity Incentive Plan but were granted outside the plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options carry an exercise price of $56.59 per share, equal to Travere’s closing stock price on the grant date, have a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued service. The RSUs also vest over four years, with 25% vesting on each anniversary of the grant date, subject to continued service. Travere Therapeutics is a biopharmaceutical company focused on developing and delivering therapies for rare diseases.